Neurocrine Biosciences (NBIX) EBIT Growth (1y) (2011 - 2026)
Neurocrine Biosciences (NBIX) EBIT Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 25.63% |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | -1.30% |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | -14.89% |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | -46.83% |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 719.49% |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 23.29% |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | -450.06% |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | -235.28% |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | -20.32% |
| 10 | Liquidia | 5.64 Bn | 5.42 Bn | 121.79 Mn | 273.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 719.49% |
| Dec 31, 2025 | 48.52% |
| Sep 30, 2025 | 30.03% |
| Jun 30, 2025 | 0.14% |
| Mar 31, 2025 | -76.23% |
| Dec 31, 2024 | -5.52% |
| Sep 30, 2024 | 30.17% |
| Jun 30, 2024 | 97.55% |
| Mar 31, 2024 | 186.95% |
| Dec 31, 2023 | 45.36% |
| Sep 30, 2023 | 60.82% |
| Jun 30, 2023 | 34.55% |
| Mar 31, 2023 | -3,783.87% |
| Dec 31, 2022 | 384.85% |
| Sep 30, 2022 | 97.30% |
| Jun 30, 2022 | -12.90% |
| Mar 31, 2022 | -90.16% |
| Dec 31, 2021 | -150.56% |
| Sep 30, 2021 | 200.45% |
| Jun 30, 2021 | -18.02% |